View source for Daniel Peterson

'''Daniel Peterson''' is an [[United States|American]] [[physician]] in private practice in the state of [[Nevada]], and has been described as a "pioneer" in the treatment of [[chronic fatigue syndrome]] (CFS).<ref name="Patient Zero">Verrillo EF, Gellman LM (1998), "Chronic Fatigue Syndrome: A reatment Guide", Macmillan, 152p, ISBN=0312180667, [http://books.google.com/books?id=VtHlTVfToiQC&pg=PA152&lpg=PA152&dq=peterson+first+used+ampligen+in+cfs&source=web&ots=G9yDE0a_8y&sig=rjllhpnZ_YSyGCcWI1W5pJk3GJ8&hl=en&sa=X&oi=book_result&resnum=2&ct=result 20090606]</ref><ref name="HHV6BOD">(2004), "HHV-6 Foundation Board of Directors", HHV-6 Foundation, [http://www.hhv-6foundation.org/bod.htm 20090318]</ref> He graduated from the University of Rochester School of Medicine, [[Rochester]], New York, in 1976 and was an intern and resident at the [[University of Utah Medical Center]] from 1976-1979. In 1979 he became a diplomat of the [[American Board of Internal Medicine]].<ref name="WPInst">(2008), "Executive staff", The Whittemore Peterson Institute, [http://www.wpinstitute.org/about/about_execboard.html 20090111]</ref> He is president of Sierra Internal Medicine of [[Incline Village]], established in 1981.<ref name="Sierra">
(2008), "Sierra Internal Medicine", Dun and Bradstreet, [http://www.manta.com/coms2/dnbcompany_f4xfgj 20090112]</ref>

==Work on myalgic encephalomyelitis / chronic fatigue syndrome ==
Peterson with [[Paul Cheney]], was a treating physician at [[Incline Village]] during an outbreak of chronic fatigue syndrome that began in 1984 in the [[Lake Tahoe]] region.<ref>Donaldson S, Snyderman N, Cheney P, Bell D, DeFreitas E, Johnson H, PWC's, Pollard P, Mrs. Dailor, Lee P (1996), "Sick & Tired - Chronic Fatiguue Syndrome", Primetime Live (tv), ABC News, Mar 27, [http://abcnewsstore.go.com/webapp/wcs/stores/servlet/DSIProductDisplay?catalogId=11002&storeId=20051&productId=2013126&langId=-1&categoryId=100024 20090609]</ref> From 1984-87, the illness was recorded in 259 patients in the area by the two physicians. The Lake Tahoe outbreak became the subject of several studies by Peterson and others. In 1995 Peterson and other investigators started conducting a 10-year follow-up study on patients seen during the outbreak. The study results were published in 2001 by the [[Journal of Chronic Fatigue Syndrome]].<ref>Strickland PS, Levine PH, Peterson DL, O'Brien K, Fears T (2001), "Neuromyasthenia and Chronic Fatigue Syndrome (CFS) in Northern Nevada/California: A Ten-Year Follow-Up of an Outbreak", Journal of Chronic Fatigue Syndrome 9(3/4):3–14 [http://dceg.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?page=abstract&ID=6563&project=dceg 20090609]</ref> In the 2000 CFS documentary [[I Remember Me]], Peterson was interviewed about some of his experiences during the Lake Tahoe outbreak.<ref>Snyder KA (2000), ''I Remember Me'', Loka Motion Productions, Inc., [http://irememberme.com/ 20090609]</ref> 

In [[1988]], Peterson was the first physician to treat an extremely ill person diagnosed with CFS with the experimental drug [[Ampligen]] by obtaining compassionate use permission from the [[U.S. Food and Drug Administration]]. [[Quantitative]] improvement in the first patient enabled the next pilot study of Ampligen in CFS patients by Peterson and other researchers. During the 1990 CFIDS Conference in [[Charlotte]], [[North Carolina]], Peterson described positive results in 15 CFS patents after he treated them with Ampligen for approximately 6 months.<ref name="Patient Zero"/> In 1990 and 1991 Peterson was one of four principal investigators for the FDA approved phase II randomized [[placebo]] controlled [[double blind]] study of the experimental [[intravenous]] drug Ampligen. The drug was administered in his Incline Village facility and three other sites.<ref>Johnson H (1996), "Osler's web: inside the labyrinth of the chronic fatigue syndrome epidemic", New York: Crown Publishers, p385, ISBN 0-517-70353-X</ref> Peterson and others reported there was statistically significant improvement in the patients receiving Ampligen.<ref>Strayer DR, Carter WA, Brodsky I, ''et al.'' (1994), "A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome", Clin.Infect.Dis. Jan;18(S1):S88–95, pmid=8148460</ref> He is a principal investigator of the FDA-approved open label safety and efficacy phase III drug study of Ampligen for treatment of chronic fatigue syndrome.<ref name="Amp 511">(2005), "Study of Ampligen in Chronic Fatigue Syndrome", U.S. National Institutes of Health, Sep, [http://clinicaltrials.gov/ct2/show/NCT00215813 20090106]</ref> According to the drug developer Hemispherx Biopharma, a [[New Drug Application]] for Ampligen treatment of chronic fatigue syndrome has been filed with the FDA but has not yet been approved.<ref>(1986), Business Description: HEM Research, Inc., [http://tobaccodocuments.org/pm/2024986987-7026.html?pattern=ampligen%5Ba-z%5D%2A& 20070225]</ref><ref>"Ampligen", Hemispherx Biopharma, [http://www.hemispherx.net/content/rnd/drug_candidates.htm 20080426]</ref>

Peterson was a member of the International Chronic Fatigue Syndrome Study Group that co-authored the most widely used clinical and research description of CFS,<ref>Wyller VB (2007), "The chronic fatigue syndrome--an update", Acta neurologica Scandinavica, 187(S):7-14, pmid=17419822</ref> called the 1994 CDC definition, and the Fukuda definition.<ref>Fukuda K, Straus S, Hickie I, Sharpe M, Dobbins J, Komaroff A (1994), "The chronic fatigue syndrome: a comprehensive approach to its definition and study", International Chronic Fatigue Syndrome Study Group, Ann Intern Med, 121(12):953-9, pmid=7978722 [http://www.annals.org/cgi/content/full/121/12/953 20090609]</ref> He is a co-author of the ''Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical Working Case Definition, Diagnostic and Treatment Protocols'' initiated by [[Health Canada]] and published by an international group of researchers in [[2003]].<ref>Carruthers BM, Jain AK, DeMeirleir KL, Peterson DL, Klimas NG, Lerner AM, Bested AC, Flor-Henry P, Joshi P, Powles ACP, Sherkey JA, Van de Sande MI (2003), "Myalgic Encephalomyelitis / Chronic Fatigue Syndrome : Clinical Working case Definition, Diagnostic and Treatment Protocols", Journal of Chronic Fatigue Syndrome, 11(1):7–36, [http://www.cfids-cab.org/MESA/ccpccd.pdf 20090609]</ref><ref>Carruthers BM (2007), "Definitions and aetiology of myalgic encephalomyelitis: how the Canadian consensus clinical definition of myalgic encephalomyelitis works", J. Clin. Pathol., Feb;60(2):117–9, pmid=16935963</ref><ref>Khot A, Polmear A (2006), "Practical General Practice: Guidelines for Effective Clinical Management (5th New edition)", Elsevier Health Sciences, Apr24:419-421, ISBN 075068867X]</ref>

==Affiliations==   

Peterson was part of the founding board, and is a past president of the [[IACFS/ME|International Association for CFS/ME]],<ref name="WPInst">(2008), "Executive staff", The Whittemore Peterson Institute, [http://www.wpinstitute.org/about/about_execboard.html 20090111]</ref> a professional organization advocating for the interests of CFS researchers and clinicians worldwide.<ref name="pmid 17662750">

Friedberg F, Sohl S, Schmeizer B (2007), "Publication trends in chronic fatigue syndrome: comparisons with fibromyalgia and fatigue: 1995-2004", J Psychosom Res, Aug;63(2):143–6, pmid=17662750</ref><ref name=timesinterview>

David Tuller (2008), "Expert Q&A, Learning Firsthand about Chronic Fatigue Syndrome" Interview with Leonard Jason, Apr 30, [http://health.nytimes.com/ref/health/healthguide/esn-chronicfatigue-expert.html 20090608]</ref> He is the medical director of the Whittemore Peterson Institute for Neuro-Immune Disease.<ref name="WPInst"/> He is a member of the board of directors and the scientific advisory board of the HHV-6 Foundation,<ref name="HHV6BOD"/> a nonprofit organization promoting [[human herpesvirus 6]] (HHV-6) associated scientific and clinical research.<ref name="NINDS">"HHV-6 Foundation", National Institute of Neurological Disorders and Stroke, [http://www.ninds.nih.gov/find_people/voluntary_orgs/volorg863.htm 20090215]</ref>   
    
In 2003 he received the distinguished CFS/FM scientist, physician or healthcare worker Rudy Perpich award, and in 2007 received the Nelson Gantz Outstanding Clinician Award from the International Association for CFS/ME.<ref name="IACFS/ME awardees">"Former IACFS/ME awardees", International Association for CFS/ME, [http://www.iacfsme.org/FormerIACFSAwardees/tabid/209/Default.aspx 20090107]</ref>   

In 1999 Peterson was commended by the Assembly and Senate of the State of Nevada, for his work and dedication to persons with chronic fatigue syndrome.<ref name="AJR14">(1999), "AJR14", Nevada Legislative Counsel Bureau, Apr 8, [http://www.leg.state.nv.us/70th/reports/History.cfm?BILLNAME=AJR14 20090217]</ref>

==Selected publications==   
* Shetzline SE, Martinand-Mari C, Reichenbach NL, Buletic Z, Lebleu B, Pfleiderer W, Charubala R, De Meirleir K, De Becker P, Peterson DL, Herst CV, Englebienne P, Suhadolnik RJ (2002), "Structural and functional features of the 37-kDa 2-5A-dependent RNase L in chronic fatigue syndrome", J. Interferon Cytokine Res., Apr;22(4):443–56, pmid=12034027
* Ablashi DV, Eastman HB, Owen CB, Roman MM, Friedman J, Zabriskie JB, Peterson DL, Pearson GR, Whitman JE (2000), "Frequent HHV-6 reactivation in multiple sclerosis (MS) and chronic fatigue syndrome (CFS) patients", J. Clin. Virol., May;16(3):179–91, pmid=10738137 [http://linkinghub.elsevier.com/retrieve/pii/S1386653299000797 20090611]  
* Suhadolnik RJ, Peterson DL, O'Brien K, Cheney PR, Herst CV, Reichenbach NL, Kon N, Horvath SE, Iacono KT, Adelson ME, De Meirleir K, De Becker P, Charubala R, Pfleiderer W (1997), "Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome", J. Interferon Cytokine Res., Jul;17(7):377–85, pmid=9243369
* Suhadolnik RJ, Reichenbach NL, Hitzges P, Adelson ME, Peterson DL, Cheney P, Salvato P, Thompson C, Loveless M, Müller WE, ''et al.'' (1994), "Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I)-poly(C12U) in chronic fatigue syndrome", In Vivo, 8(4):599–604, pmid=7893988
* Suhadolnik RJ, Reichenbach NL, Hitzges P, Sobol RW, Peterson DL, Henry B, Ablashi DV, Müller WE, Schröder HC, Carter WA, ''et al.'' (1994), "Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome", Clin. Infect. Dis., Jan;18(S1):S96–104, pmid=8148461
* Strayer DR, Carter WA, Brodsky I, Cheney P, Peterson D, Salvato P, Thompson C, Loveless M, Shapiro DE, Elsasser W, ''et al.'' (1994), "A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome", Clin. Infect. Dis., Jan;18(S1):S88–95, pmid=8148460
* Levine PH, Peterson D, McNamee FL, O'Brien K, Gridley G, Hagerty M, Brady J, Fears T, Atherton M, Hoover R (1992), "Does Chronic Fatigue Syndrome Predispose to Non-Hodgkin's Lymphoma?", Cancer Res Oct;52(S):S55l6-55l8
* Daugherty SA, Henry BE, Peterson DL, Swarts RL, Bastien S, Thomas RS (1991), "Chronic fatigue syndrome in northern Nevada", Rev Infect Dis, 13(S1):S39–44, pmid=1850542
* Caligiuri M, Murray C, Buchwald D, ''et al.'' (1987), "Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome", J Immunol, Nov;139(10):3306–13, pmid=2824604, [http://www.jimmunol.org/cgi/pmidlookup?view=long&pmid=2824604 20090611]

==References==
{{refs}}

[[Category:Myalgic encephalomyelitis]]
[[Category:Physician in the United States of America]]